Journal article
Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary
A Posner, T Sivakumaran, A Pattison, D Etemadmoghadam, N Thio, C Wood, K Fisher, S Webb, A Defazio, N Wilcken, B Gao, CS Karapetis, M Singh, IM Collins, G Richardson, C Steer, M Warren, N Karanth, A Fellowes, SB Fox Show all
Journal for Immunotherapy of Cancer | BMJ PUBLISHING GROUP | Published : 2023
Abstract
Background Cancer of unknown primary (CUP) is a heterogeneous group of metastatic cancers where a primary tissue of origin (TOO) is uncertain. Most patients with CUP have limited treatment options and poor survival outcomes. Immune checkpoint inhibitors (ICIs) can be efficacious in some patients with CUP, but the optimal predictive biomarkers are unknown. We therefore assessed immune and genomic biomarkers as well as predicted TOO in patients with CUP, including a subset treated with ICIs. Methods Patients with CUP were subject to gene-expression profiling (GEP) and DNA panel sequencing. Immune and stromal-related gene expression was explored by NanoString, including genes associated with im..
View full abstractGrants
Awarded by University of Sydney
Funding Acknowledgements
We acknowledge Cameron Patrick of the Melbourne Statistical Consulting Platform for providing statistical support. We wish to thank Jillian Hung and Niklyn Nevins, SUPER study coordinators at Westmead and Blacktown, Lisa Kay at Nepean, Karin Lyon (ethics and governance), and acknowledge the contributions of the Nepean Cancer Biobank and the Westmead GynBiobank (funded by the Cancer Institute NSW, NHMRC and the Department of Gynaecological Oncology, Westmead Hospital) for facilitating the study. We wish to acknowledge the patients who have contributed to this study and the CUP consumer steering committee, Cindy Bryant (chair), Kym Sheehan, Christine Bradford, Clare Brophy, Dale Witton, and Frank Stoss.